The deal is set for completion in Q1 2025. Credit: afotostock via Shutterstock. BioNTech has signed a definitive agreement to ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

16 analysts have expressed a variety of opinions on BioNTech BNTX over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

It’s a jungle out there. Deriving the right royalty rate for new pharmaceuticals and biotechnologies is a real tangle. This is a critical business function, and it has never been more important ...

In the latest quarter, 15 analysts provided ratings for BioNTech BNTX, showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net profit of 198.1 million euros or 0.81 euros per share for the third quarter ...